Dr. @IbiayiMD will discuss #BRAF (both V600E and non) in NSCLC at #DCLung23 on Saturday, October 7, 2023. How should we sequence therapy in this important subtype? New options? Full agenda, faculty and registration at: medstarhealth.org/dclung23

Registration is open! Join @IbiayiMD of @MGHCancerCenter as she chairs an @OncLiveSOSS Lung Cancer in-person education and networking event on 6/21 at 6:00 PM! #SOSS

Register Today: ow.ly/PfIy50OpvGf

Online @PeerView CME activity now available with Dr. @IbiayiMD and me discussing "Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy?"

lrn.peerview.com/150207968_1/15…

Tomorrow! Multi-tumor symposium with @DrNeilLove & Research to Practice, live or virtual, with the North Carolina Oncology Association & South Carolina Oncology Society 2023 meeting. Dr. @IbiayiMD and I will discuss the lung cancer updates! Register now!

researchtopractice.com/Meetings/NCOA-…

MET amp identified at resistance to 2nd-gen ALK TKIs (12%) and lorlatinib (22%). ALK+ NSCLC with MET amp responds to lorlatinib + crizotinib. Phase I/II trial coming soon. We must test for MET amp. #ALKpositive
clincancerres.aacrjournals.org/content/early/…

#7PhotosOfMyLife challenged by
@LeciaSequist

no comments no people. Today is day 2 and I challenge
@MMarmarelis

#7PhotosOfMyLife challenged by
@LeciaSequist
no comments no people. Today is day 1 and I challenge
@BeccaHeistMD